Galectin Therapeutics (GALT) Financials

$3.91

$0.01 (0.23%)

As on 11-Sep-2026 12:37EDT

Market cap

$465 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

207.7

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	--	--	0.04	0.03	0.03	0.04
Gross Profit	--	--	-0.04	-0.03	-0.03	-0.04
Operating Expenses	15.62	20.09	42.43	38.07	38.35	30.18
Operating Profit (EBIT)	-15.62	-20.09	-42.43	-38.07	-38.35	-30.18
Other Income	--	--	--	--	--	--
Profit before Tax	-27.84	-30.84	-47.05	-41.07	-38.78	-30.53
Provision for Tax	--	--	--	-2.99	0.42	0.45
Profit after Tax (Net Income)	-27.84	-30.84	-47.05	-41.07	-38.78	-30.53
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-38.87	-30.70

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	-136.85	-126.20	-103.07	-60.24	-32.19	2.62
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	0.06	137.70	85.16	72.77	40.47	30.18
Current Liabilities	151.62	8.03	35.41	15.68	13.01	9.03
Total Liabilities	166.45	19.53	17.50	28.20	21.29	41.83

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	0.17	0.10	0.24	0.49	0.73	0.01
Current Assets	14.66	19.44	17.25	27.71	20.55	41.82
Total Assets	166.45	19.53	17.50	28.20	21.29	41.83
Total Debt*	137.70	133.76	106.25	71.81	39.87	29.06
Net Current Assets	-136.96	11.41	-18.16	12.03	7.54	32.79

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-23.88	-41.77	-32.97	-31.06	-24.31
Cash Flow from Investing Activities	--	--	--	--	--	--
Cash from Financing Activities	--	26.48	31.23	40.03	10.00	36.81
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-0.43	-0.48	-0.75	-0.68	-0.65	-0.52
Cash EPS ($)	--	-0.48	-0.75	-0.68	-0.65	-0.52
Adjusted Book Value ($)	--	--	--	--	--	0.04
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.37	-0.67	-0.55	-0.52	-0.42
Free Cash Flow per Share ($)	--	-0.37	-0.67	-0.55	-0.52	-0.42

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-574.39	-638.31	-426.88	-197.10	-109.20
ROE (%)	--	26.90	57.62	88.85	262.19	-227.74
ROA (%)	-28.88	-166.56	-205.92	-165.97	-122.88	-85.48
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	--	--	--	--	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	80.27	43.37	-8.45	-1.41	-25.65	-28.49
Net Profit Growth (%)	30.98	34.46	-14.56	-5.91	-27.02	-30.10
EPS Growth (%)	33.22	0.36	-0.10	-0.05	-0.25	-0.27
Book Value Growth (%)	-12.50	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-8.62	-1.72	-2.43	-1.73	-3.97
Price / Book Value	207.70	-2.11	-0.79	-1.66	-2.09	46.31
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-4.04	-16.28	-4.15	-3.82	-2.34	-3.69
Close Price ($)	4.64	4.16	1.29	1.66	1.13	2.07
High Price ($)	7.13	7.13	4.27	2.47	2.57	5.70
Low Price ($)	2.03	1.07	0.73	1.07	1.02	1.82
Market Cap ($ Cr)	464.92	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	-1.06	-1.03	-1.19	-1.24	11.11
Short term debt to equity ratio	-1.01	0.00	-0.21	0.00	0.00	0.00
Current Ratio	0.10	2.42	0.49	1.77	1.58	4.63
Quick Ratio	0.10	--	--	--	--	--
Interest Coverage	-2.59	-3.21	-7.49	-13.71	-36.54	-61.43

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	--	59,659.15	57,117.35	32,501.54	13,794.87
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.